"The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.
(Generic versions may still be available.)
Patients with known hypersensitivity to any of the components of the therapeutic system should not use Esclim (estradiol transdermal) . Estrogens should not be used in individuals with any of the following conditions:
4. Known or suspected estrogen-dependent neoplasia.
5. Active thrombophlebitis or thromboembolic disorders.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 1/12/2005
Additional Esclim Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.